UY34952A - METHOD FOR TREATMENT OF SKIN DISORDERS - Google Patents

METHOD FOR TREATMENT OF SKIN DISORDERS

Info

Publication number
UY34952A
UY34952A UY34952A UY34952A UY34952A UY 34952 A UY34952 A UY 34952A UY 34952 A UY34952 A UY 34952A UY 34952 A UY34952 A UY 34952A UY 34952 A UY34952 A UY 34952A
Authority
UY
Uruguay
Prior art keywords
viral
skin
treatment
infection
skin disorders
Prior art date
Application number
UY34952A
Other languages
Spanish (es)
Inventor
Primor Naftali
Original Assignee
S I S Shulov Innovative Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S I S Shulov Innovative Science Ltd filed Critical S I S Shulov Innovative Science Ltd
Priority to UY34952A priority Critical patent/UY34952A/en
Publication of UY34952A publication Critical patent/UY34952A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica tópica para tratar un trastorno de la piel que se selecciona del grupo que consiste de infección viral por herpes, infección viral por varicela, erupción, picaduras de insecto, picaduras de medusa, quemaduras, psoriasis, picazón, respuesta alérgica de la piel, lesiones cutáneas a resultado de un efecto secundario o complicaciones de una droga o tratamiento médico e hipopigmentación. La composición comprende un péptido de la fórmula pGLU-X-Y-Z, donde X, Y y Z son aminoácidos, con o sin un grupo alquilo, y un excipiente farmacéuticamente aceptableA topical pharmaceutical composition to treat a skin disorder that is selected from the group consisting of viral herpes infection, viral chickenpox infection, rash, insect bites, jellyfish stings, burns, psoriasis, itching, allergic skin response , skin lesions as a result of a side effect or complications of a drug or medical treatment and hypopigmentation. The composition comprises a peptide of the formula pGLU-X-Y-Z, where X, Y and Z are amino acids, with or without an alkyl group, and a pharmaceutically acceptable excipient

UY34952A 2013-07-30 2013-07-30 METHOD FOR TREATMENT OF SKIN DISORDERS UY34952A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY34952A UY34952A (en) 2013-07-30 2013-07-30 METHOD FOR TREATMENT OF SKIN DISORDERS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY34952A UY34952A (en) 2013-07-30 2013-07-30 METHOD FOR TREATMENT OF SKIN DISORDERS

Publications (1)

Publication Number Publication Date
UY34952A true UY34952A (en) 2015-02-27

Family

ID=52705340

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34952A UY34952A (en) 2013-07-30 2013-07-30 METHOD FOR TREATMENT OF SKIN DISORDERS

Country Status (1)

Country Link
UY (1) UY34952A (en)

Similar Documents

Publication Publication Date Title
MX2019004616A (en) Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors.
CO2019007810A2 (en) Amino-triazolopyridine compounds and their use in the treatment of cancer
DOP2015000240A (en) 3- PYRIMIDIN- 4- IL- OXAZOLIDIN- 2- WAVES AS MUTANT HDI INHIBITORS
ECSP18073726A (en) WDR5 PROTEIN-PROTEIN BOND INHIBITORS
BR112017016006A2 (en) compound, pharmaceutical composition, method of treating diseases and conditions, use of a compound and a combination, and, combination.
ECSP19025350A (en) MONOCLONAL ANTIBODIES OPTIMIZED AGAINST THE TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
EA201890859A1 (en) PREVENTION, TREATMENT AND TREATMENT OF DEVELOPMENT OF DISEASE WITH THE APPLICATION OF THERAPEUTICALLY EFFECTIVE QUANTITIES OF ACTIVATED FATTY ACIDS
CL2020000408A1 (en) Solid crystalline forms of a bet inhibitor. (divisional application 201803702).
AR113803A1 (en) PYRIMIDINE COMPOUND AS INHIBITOR OF JAK KINASES
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
BR112017026057A2 (en) prodrugs consisting of a hyaluronic acid linker conjugate and a double glp-1 / glucagon agonist
UA112446C2 (en) APPLICATION OF omega-fatty acids for the treatment of diseases
MX2019001633A (en) Silk-derived protein for treating inflammation.
UY38293A (en) NEW FIMH ANTAGONISTS C-MANOSIDE COMPOUNDS AND COMPOSITIONS
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
CO2024005925A2 (en) Small molecules for cancer treatment
EA202091446A1 (en) METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
BR112017012844A2 (en) substituted pyridyl cycloalkyl carboxylic acids, compositions containing them and their medical uses
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201592242A1 (en) PYRIDON DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
CO2019007186A2 (en) Ror gamma modulators (rorγ)
EA201591704A1 (en) NEW SUSTAINABLE SALTS OF PENTADECEPEPTIDE, METHOD OF THEIR PRODUCTION, THEIR APPLICATION IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THERAPY
AR104721A1 (en) HUMAN FAB ANTI-NGF FRAGMENT
UY34952A (en) METHOD FOR TREATMENT OF SKIN DISORDERS

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20220506